Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

McKesson
Merck
Harvard Business School
Medtronic
Johnson and Johnson
Moodys

Last Updated: December 10, 2019

DrugPatentWatch Database Preview

Details for Patent: 7,985,418

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Which drugs does patent 7,985,418 protect, and when does it expire?

Patent 7,985,418 protects RENVELA and is included in one NDA.

This patent has twenty-four patent family members in seventeen countries.

Summary for Patent: 7,985,418
Title:Aliphatic amine polymer salts for tableting
Abstract: The tablets, compositions and methods of the present invention, comprising a carbonate salt of an aliphatic amine polymer and s monovalent anion can prevent or ameliorate acidosis, in particular acidosis in patients with renal disease. The tablets and compositions of the present invention maintain a disintegration time of no greater than 30 minutes at 37.degree. C. and at pH of at least 1 for a period of at least ten weeks at 60.degree. C. Furthermore, the tablets are stable for extended periods of time without the need for specialized storage conditions.
Inventor(s): Bhagat; Hitesh R. (Wayland, MA), Goldberg; Jeffrey M. (Framingham, MA), Harianawala; Abizer I. (Lexington, MA), Brenner; Louis (Brookline, MA)
Assignee: Genzyme Corporation (Cambridge, MA)
Application Number:11/262,291
Patent Claim Types:
see list of patent claims
Dosage form; Composition;

Drugs Protected by US Patent 7,985,418

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Sanofi RENVELA sevelamer carbonate TABLET;ORAL 022127-001 Oct 19, 2007 AB RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 7,985,418

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2005302243   Start Trial
Brazil PI0517916   Start Trial
Canada 2586023   Start Trial
Canada 2762076   Start Trial
China 101043878   Start Trial
China 102824322   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Merck
Moodys
McKinsey
Boehringer Ingelheim
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.